This suggests that genetic variations in ACE2 may be considered when prescribing ACE inhibitors for hypertension management.[41] The REGRESS study examined the influence of apolipoprotein E (APOE) polymorphism on the response to pravastatin therapy in men with CAD. The gene discussed is ACE; the disease is coronary artery disorder.